We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Complete response in high-grade serous ovarian cancer: luck by chance or predictable chemosensitivity?
- Authors
Matei, Radu; Stolojanu, Anca; Siminiceanu, Crina; Dumitrescu, Elena; Ciontea, Loredana; Stănculeanu, Dana-Lucia
- Abstract
Introduction. Ovarian cancer is an underlying cause of mortality among women. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer and is responsible for a disproportionate share of the fatalities. Despite the grim outlook, tailored therapy alongside early diagnosis improve the prognostic outcome. Case presentation. We report the case of a 34-year-old female, with a personal history of minor thalassemia, who was diagnosed with bilateral high-grade serous ovarian cancer (HGSOC), stage FIGO IIIB, pT3b pNO pM0, hormone receptor-positive, BRCA1 mutation positive. The patient underwent radical surgery with comprehensive staging and debulking. After recovery, the primary therapy was initiated with paclitaxel/ carboplatin alongside bevacizumab, summing a total of six series during the span of four months. Imagistic evaluation was performed, and complete response was confirmed. Maintenance therapy with olaparib and bevacizumab was subsequently instituted. After six months of maintenance therapy, an imagistic reevaluation was performed, confirming the complete remission, and maintenance therapy was further continued. The up-to-present fortunate evolution may take an unexpected turn as the patient is infected with Borrelia burgdorferi, a pathogen with pro-oncogenic potential and tumor heterogeneity promoter properties in gynecological neoplastic disease. Conclusions. This case further strengthens the premises regarding the positive response rate of HGSOC hormone receptor positive to platinum-based chemotherapy, the overall survival rate and the progression-free survival. This report aims to additionally present the limited data on Lyme disease in gynecological cancers.
- Subjects
OVARIAN cancer; CARCINOGENS; FEMALE reproductive organ diseases; PROGRESSION-free survival; BORRELIA burgdorferi; BETA-Thalassemia
- Publication
Oncolog-Hematolog, 2023, Issue 64, p38
- ISSN
2066-8716
- Publication type
Article